Laurence Albigès, MD, PhD, on the Potential Impact of Immunotherapy-Based Combinations in Advanced RCC

Laurence Albigès, MD, PhD, discusses how immunotherapy combinations have affected the treatment landscape for previously untreated advanced or metastatic renal cell carcinoma.

Laurence Albigès, MD, PhD, a medical oncologist and head of the Genitourinary Unit at Gustave Roussy in Villejuif, who spoke with CancerNetwork® during the 2022 Genitourinary Cancers Symposium highlighted how treatment with immunotherapy-based combinations have had an impact on the treatment landscape for previously untreated advanced or metastatic renal cell carcinoma.

In particular, she referenced the improved overall survival (OS) benefit evident with this treatment strategy across the population, as well as a need for a personalized approaches to treating patients.


The first-line landscape has evolved greatly over time and we now have a standard of care combination approach in all our patients for clear cell RCC in the frontline. What we see is that we are impacting OS in our patients. These trials [involving immunotherapy-based combinations] have changed the landscape and the expected OS benefit for our patients. We moved from a median of about 24 months to now 48 months, if we think about nivolumab plus ipilimumab, [for example]. We have greatly increased the overall survival of our patients. This is impacting our treatment strategy in all countries where we have access to different regimens. We now need to tailor [treatment] a bit more to define what combination is most appropriate for [an individual] patient.


Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up. J Clin Oncol. 2022;40(suppl 6):352. doi:10.1200/JCO.2022.40.6_suppl.352

Related Videos
Experts on RCC
Experts on RCC
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Experts on RCC
Experts on RCC
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Related Content